Latest Financials News

Emeco Holdings has refinanced its long-term debt with a new A$355 million facility, extending maturity and improving terms to support future growth.

Altech Batteries Limited has undergone a significant board and management reshuffle following a shareholder-led challenge, appointing new leadership while reaffirming its strategic focus on advanced battery technologies.

CD Private Equity Fund III reported a $3.02 million net loss for the half-year ending September 2025, driven largely by foreign currency translation losses, yet maintained a 10 cent per unit distribution supported by portfolio realisations and cash management.

CD Private Equity Fund II reported a reduced net loss of $2.43 million for the half-year to September 2025, supported by $9.45 million in distributions from portfolio realisations. Despite foreign exchange headwinds, the Fund maintains a diversified portfolio and a positive long-term return track record.

CD Private Equity Fund I reported a $2.6 million net loss for the half-year ended 30 September 2025, driven by foreign exchange impacts and fair value adjustments, while distributing 8 cents per unit amid ongoing portfolio realisations.

TruScreen Group Limited reported a 17% decline in first half FY2026 product sales but affirmed full-year revenue guidance at NZ$2.8 million, supported by strategic expansions and a successful NZ$4 million capital raise.

Vysarn Limited has reported record FY25 profits and is aiming for a 33% NPBT increase in FY26, driven by acquisitions and progress on the Kariyarra Water Scheme. The company is expanding its national footprint amid growing water demand in mining and infrastructure sectors.

Coronado Global Resources has finalized its financial support agreement with Stanwell Corporation, cementing previously disclosed terms and providing clarity on its capital position.

Joyce Group reported solid FY25 results with strong revenue growth and a 20% expansion in KWB showrooms, alongside a key leadership transition at KWB.

Amplia Therapeutics reported a $4.18 million half-year loss but bolstered its cash reserves with a $27.6 million capital raise to advance clinical trials of its lead drug narmafotinib, showing encouraging interim data in pancreatic cancer.

The Federal Court of Australia has approved the acquisition scheme for Lynch Group Holdings, paving the way for a cash payout to shareholders and imminent trading suspension.

QGold Pty Ltd has initiated an unconditional on-market takeover offer for all shares in Venus Metals Corporation Limited at a 21% premium, aiming to consolidate control and potentially delist the explorer.